← SynDRA
BEXAROTENE
SynDRA canonical compound SYN0003202 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | RXRG |
|---|
| Mechanism of action | Retinoid receptor agonist |
|---|
| Indication | cutaneous T-cell lymphoma (CTCL) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- RXRA
- RXRG
- RXRB
- PPARG
- ABCA1
- RARB
- Rxrb
- Rxra
- RARG
- RARA
- CYP26A1
- NR1H3
Mechanisms of action (all sources)
- Retinoid receptor agonist
- RXRB AGONIST
- Retinoid X receptor agonist
- RXRG AGONIST
- RXRA AGONIST
- PPARG ANTAGONIST
- RXRA MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADORA3
- ADRA1A
- TPI1
- CHRM1
- TBXA2R
- PGR
- ESR1
- SLC6A2
- ABCB11
- RECQL
- PDE3A
- PDE4A
- PTGS1
- SLC6A4
- SLC6A3
- MAOA
- TDP1
- USP1
- OPRM1
- KAT2A
- KDR
- KCNH2
- ACHE
- HTR2B
- HTR1A
- HSPA5
- HRH3
- HDAC6
- F2
- DRD1
- CHRM2
- BLM
- AR
- ADRA2A
- VDR
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ACM1
- ANDR
- TSHR
- TP53
- SYK
- PRGR
- PPM1D
- NTMT1
- NTM1A
- NR4A2
- KSYK
- HSPB1
- GPX4
- GCR
- ESRRA
- ESR2
- CP3A7
- CP2C9
- CP19A
- CASP7
- CASP3
- UBP1
Drug classes
- Antineoplastic Agents
- Retinoid
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- TARGRETIN
- Targretin
- LGD 1069
- targretin
- targretyn
- targrexin
- Bexaroteno
- LG-100069
- LG100069
- LGD-1069
- LGD1069
- NSC-747528
- Targretine
- Bexarotenum
- Targret
- Targretyn
- Targrexin
- Bexarotene [USAN]
- Elan brand of bexarotene;Ligand brand of bexarotene
- LG 1069
- LG1069
- LG69 compound
- Targretin (TN)
- Targretin-gel
- Bexarotene (USAN/INN)
- 3-methyl-TTNEB
- 9RA
- NSC 747528
- CHEMBL1023
- CHEBI:50859
- A61RXM4375
- NCGC00181016-01
- Ro 26-4455
- SR 11247
- bexaroteno
- bexarotenum
- Bexaroten
Reported adverse events
- Headache
- Infection
- Rash
- Alopecia
- Cataract
- Chills
- Hypothyroidism
- Insomnia
- Nausea
- Vomiting
- Asthenia
- Leukopenia
Look up BEXAROTENE in the interactive SynDRA portal →